Dimensional Fund Advisors
SYRS

Dimensional Fund Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Dimensional Fund Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,015
Closed -$37.8K – 3514
2023
Q2 		$37.8K Sell
12,015
-18,211
-60% -$58.5K ﹤0.01% 3421
2023
Q1 		$80.7K Hold
30,226
– – ﹤0.01% 3332
2022
Q4 		$109 Buy
30,226
+702
+2% +$3.05K ﹤0.01% 3314
2022
Q3 		$190K Buy
+29,524
New +$240K ﹤0.01% 3249
2022
Q2 		– Sell
-22,107
Closed -$263K – 3540
2022
Q1 		$263K Sell
22,107
-9,413
-30% -$168K ﹤0.01% 3271
2021
Q4 		$1.03M Buy
31,520
+10,990
+54% +$445K ﹤0.01% 3026
2021
Q3 		$918K Sell
20,530
-10,335
-33% -$505K ﹤0.01% 3062
2021
Q2 		$1.68M Sell
30,865
-4,252
-12% -$252K ﹤0.01% 2917
2021
Q1 		$2.63M Sell
35,117
-15,391
-30% -$1.6M ﹤0.01% 2781
2020
Q4 		$5.48M Sell
50,508
-5,772
-10% -$527K ﹤0.01% 2496
2020
Q3 		$4.98M Sell
56,280
-97
-0.2% -$11K ﹤0.01% 2446
2020
Q2 		$6.01M Hold
56,377
– – ﹤0.01% 2415
2020
Q1 		$3.34M Buy
56,377
+6,224
+12% +$422K ﹤0.01% 2545
2019
Q4 		$3.47M Buy
50,153
+2,691
+6% +$163K ﹤0.01% 2719
2019
Q3 		$4.93M Hold
47,462
– – ﹤0.01% 2602
2019
Q2 		$4.39M Buy
47,462
+11,118
+31% +$774K ﹤0.01% 2676
2019
Q1 		$3.32M Buy
36,344
+11,936
+49% +$831K ﹤0.01% 2772
2018
Q4 		$1.36M Buy
24,408
+9,373
+62% +$712K ﹤0.01% 2954
2018
Q3 		$1.79M Buy
+15,035
New +$1.74M ﹤0.01% 2948

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Dimensional Fund Advisors's SYRS Position: Q3 2023 in Review

Dimensional Fund Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2023, closing a stake of 12,015 shares — an estimated $37.8K sold.

Dimensional Fund Advisors first reported a position in SYRS in Q3 2018 and held it in 19 quarters. The position peaked at $6.01M in Q2 2020. 48 funds tracked by Wall St. Rank hold SYRS as of Q3 2023.

  • Dimensional Fund Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 12,015 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $37.8K.
  • Dimensional Fund Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 19 quarters.
  • Dimensional Fund Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $6.01M in Q2 2020.
  • 48 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Dimensional Fund Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.